Policy and Regulatory Report | May.24.2012
This article, about an appeal in AstraZeneca's antitrust case, quotes London antitrust and competition partner Douglas Lahnborg.
The opinion presents “no major surprises for the industry,” said Douglas Lahnborg, a London-based lawyer. “The pharmaceutical industry has moved on quite a lot since the Commission's decision.”
He recognized that the Court of Justice doesn't always follow the recommendation made by the Advocate General.
“However, here the key findings of a Commission decision were upheld by the General Court whose ruling has been upheld by the Advocate General,” he added. “It would be very difficult for AstraZeneca to turn this around.”